Literature DB >> 16634039

Tumor necrosis factor-alpha contributes to below-level neuropathic pain after spinal cord injury.

Xiang-min Peng1, Zhi-gang Zhou, Joseph C Glorioso, David J Fink, Marina Mata.   

Abstract

OBJECTIVE: Our objective was to elucidate the mechanisms responsible for below-level pain after partial spinal cord injury (SCI).
METHODS: We used lateral hemisection to model central neuropathic pain and herpes simplex viral (HSV) vector-mediated transfer of the cleaved soluble receptor for tumor necrosis factor-alpha (TNF-alpha) to evaluate the role of TNF-alpha in the pathogenesis of below-level pain.
RESULTS: We found activation of microglia and increased expression of TNF-alpha below the level of the lesion in the lumbar spinal cord after T13 lateral hemisection that correlated with emergence of mechanical allodynia in the hind limbs of rats. Lumbar TNF-alpha had an apparent molecular weight of 27 kDa, consistent with the full-length transmembrane form of the protein (mTNF-alpha). Expression of the p55 TNF soluble receptor (sTNFRs) by HSV-mediated gene transfer resulted in reduced pain behavior and a decreased number of ED1-positive cells, as well as decreased phosphorylation of the p38 MAP kinase (p-p38) and diminished expression of mTNF-alpha in the dorsal horn.
INTERPRETATION: These results suggest that expression of mTNF-alpha after injury is related to development of pain, and that reverse signaling through mTNF-alpha by sTNFR at that level reduces cellular markers of inflammatory response and pain-related behavior.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16634039     DOI: 10.1002/ana.20855

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  61 in total

Review 1.  Gene therapy for the treatment of chronic peripheral nervous system pain.

Authors:  William F Goins; Justus B Cohen; Joseph C Glorioso
Journal:  Neurobiol Dis       Date:  2012-06-02       Impact factor: 5.996

2.  Validity of acute and chronic tactile sensory testing after spinal cord injury in rats.

Authors:  Megan Ryan Detloff; Leslie M Clark; Karen J Hutchinson; Anne D Kloos; Lesley C Fisher; D Michele Basso
Journal:  Exp Neurol       Date:  2010-07-17       Impact factor: 5.330

3.  In vivo longitudinal MRI and behavioral studies in experimental spinal cord injury.

Authors:  Laura M Sundberg; Juan J Herrera; Ponnada A Narayana
Journal:  J Neurotrauma       Date:  2010-10-09       Impact factor: 5.269

4.  Herpes simplex virus vector-mediated expression of interleukin-10 reduces below-level central neuropathic pain after spinal cord injury.

Authors:  Darryl Lau; Steven E Harte; Thomas J Morrow; Shiyong Wang; Marina Mata; David J Fink
Journal:  Neurorehabil Neural Repair       Date:  2012-05-15       Impact factor: 3.919

5.  Inhibition of NOX2 signaling limits pain-related behavior and improves motor function in male mice after spinal cord injury: Participation of IL-10/miR-155 pathways.

Authors:  Boris Sabirzhanov; Yun Li; Marino Coll-Miro; Jessica J Matyas; Junyun He; Alok Kumar; Nicole Ward; Jingwen Yu; Alan I Faden; Junfang Wu
Journal:  Brain Behav Immun       Date:  2019-02-23       Impact factor: 7.217

Review 6.  Viral vector-based gene transfer for treatment of chronic pain.

Authors:  Shuanglin Hao; Marina Mata; David J Fink
Journal:  Int Anesthesiol Clin       Date:  2007

7.  Activation of spinal and supraspinal cannabinoid-1 receptors leads to antinociception in a rat model of neuropathic spinal cord injury pain.

Authors:  Aldric Hama; Jacqueline Sagen
Journal:  Brain Res       Date:  2011-07-26       Impact factor: 3.252

8.  Remote activation of microglia and pro-inflammatory cytokines predict the onset and severity of below-level neuropathic pain after spinal cord injury in rats.

Authors:  Megan Ryan Detloff; Lesley C Fisher; Violetta McGaughy; Erin E Longbrake; Phillip G Popovich; D Michele Basso
Journal:  Exp Neurol       Date:  2008-04-20       Impact factor: 5.330

9.  Soluble Nogo receptor down-regulates expression of neuronal Nogo-A to enhance axonal regeneration.

Authors:  Xiangmin Peng; Zhigang Zhou; Jian Hu; David J Fink; Marina Mata
Journal:  J Biol Chem       Date:  2009-11-09       Impact factor: 5.157

Review 10.  HSV gene transfer in the treatment of chronic pain.

Authors:  David J Fink; Marina Mata
Journal:  Sheng Li Xue Bao       Date:  2008-10-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.